Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Patient enrollment completed for phase III studies of pramlintide

March 20, 1998

Fluoxetine for premature ejaculation

March 20, 1998

Lilly reveals new series of hypoglycemic/hypolipidemic compounds

March 20, 1998

PD-72953 raises HDL by activating a peroxisomal receptor?

March 20, 1998

SmithKline Beecham and Ligand begin leptin-obesity collaboration

March 19, 1998

Ixion succeeds in lowering urinary oxalate levels with IxC1-62/47

March 19, 1998

Analysis of statin results confirms beneficial clinical effects of lipid lowering on mortality

March 19, 1998

BB-10010 has myelosuppressive and progenitor cell-mobilizing effects in humans

March 19, 1998

EntreMed's therapy for insufficient tissue oxygenation heading for clinic

March 18, 1998

European patent covers Bayer's new HMG-CoA reductase inhibitors

March 18, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...